Pipeline Expansion
Selective product in-licensing or acquisition will enable Context Therapeutics to rapidly build a diversified pipeline of drugs to treat hormone response cancers.
SOURCE. Academia, startup, or pharma.
STAGE. Preclinical development through Phase 2-ready.
TYPE. Small molecule or biologic.
Our Science
Developing bispecific antibody therapies to target CLDN6-positive cancers, including non-small cell lung, testicular, and ovarian.
Our Pipeline
Context’s lead candidate, CTIM-76, is a CLDN6 x CD3 bispecific antibody.